{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:53:09Z","timestamp":1786737189513,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pathol Microbiol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijpm.ijpm_783_19","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T03:38:12Z","timestamp":1598240292000},"page":"418","source":"Crossref","is-referenced-by-count":6,"title":["Can TROP2 be used as a prognostic marker in endometrioid endometrial carcinoma?"],"prefix":"10.4103","volume":"63","author":[{"given":"\u00d6zg\u00fcr\u0130lhan","family":"\u00c7elik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SerkanY","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0377-4929.291691-1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6890-12-22","article-title":"Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma","author":"Bignotti","year":"2012","journal-title":"BMC Clin Pathol"},{"key":"key-10.4103\/0377-4929.291691-2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics-2012","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0377-4929.291691-3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2017.12.021","article-title":"Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis","author":"Sud","year":"2018","journal-title":"Gynecol Oncol"},{"key":"key-10.4103\/0377-4929.291691-4","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH. Tumours of the uterine corpus. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon, France: IARCH; 2014. p. 121-54."},{"key":"key-10.4103\/0377-4929.291691-5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.path.2016.04.006","article-title":"Molecular pathology, predictive, prognostic, and diagnostic markers in uterine tumors","author":"Ritterhouse","year":"2016","journal-title":"Surg Pathol"},{"key":"key-10.4103\/0377-4929.291691-6","first-page":"353","article-title":"Markers for individualised therapy in endometrial carcinoma","author":"Salvesen","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0377-4929.291691-7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GCO.0000000000000432","article-title":"The target invites a foe: Antibody-drug conjugates in gynecologic oncology","author":"Campos","year":"2018","journal-title":"Curr Opin Obstet Gynecol"},{"key":"key-10.4103\/0377-4929.291691-8","first-page":"84","article-title":"Trop 2 and its overexpression in cancers: Regulation and clinical\/therapeutic implications","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"key-10.4103\/0377-4929.291691-9","doi-asserted-by":"crossref","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: A systematic review and meta-analysis","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"key":"key-10.4103\/0377-4929.291691-10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4132\/jptm.2017.10.17","article-title":"The significance of TROP2 expression in predicting BRAF mutations in papillary thyroid carcinoma","author":"Kong","year":"2018","journal-title":"J Pathol Trans Med"},{"key":"key-10.4103\/0377-4929.291691-11","first-page":"1","article-title":"Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19","author":"Murtezaoglu","year":"2017","journal-title":"Pol J Pathol"},{"key":"key-10.4103\/0377-4929.291691-12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.ajpath.2018.05.016","article-title":"Characterization of peribiliary gland-constituting cells based on differential expression of Trophoblast cell surface protein 2 in biliary tract","author":"Matsui","year":"2018","journal-title":"Am J Pathol"},{"key":"key-10.4103\/0377-4929.291691-13","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.prp.2018.07.017","article-title":"High expression of TROP2 is correlated with poor prognosis of oral squamous cell carcinoma","author":"Tang","year":"2018","journal-title":"Pathol Res Pract"},{"key":"key-10.4103\/0377-4929.291691-14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","author":"Fong","year":"2008","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0377-4929.291691-15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hed.23138","article-title":"Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma","author":"Wu","year":"2013","journal-title":"Head Neck"},{"key":"key-10.4103\/0377-4929.291691-16","first-page":"10995","article-title":"Prognostic value of TROP2 in human nasopharyngeal carcinoma","author":"Guan","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key-10.4103\/0377-4929.291691-17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","article-title":"Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients","author":"Bignotti","year":"2010","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0377-4929.291691-18","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cam4.1018","article-title":"Correlation between Trop2 and amphiregulin coexpression and overall survival in gastric cancer","author":"Zhao","year":"2017","journal-title":"Cancer Med"},{"key":"key-10.4103\/0377-4929.291691-19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12935-018-0589-9","article-title":"TROP2 methylation and expression in tamoxifen-resistant breast cancer","author":"Zimmers","year":"2018","journal-title":"Cancer Cell Int"},{"key":"key-10.4103\/0377-4929.291691-20","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"key-10.4103\/0377-4929.291691-21","first-page":"515","article-title":"Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells","author":"Zhang","year":"2018","journal-title":"Int J Oncol"},{"key":"key-10.4103\/0377-4929.291691-22","doi-asserted-by":"crossref","first-page":"44492","DOI":"10.18632\/oncotarget.9876","article-title":"High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"key":"key-10.4103\/0377-4929.291691-23","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1007\/s13277-014-2469-9","article-title":"Prognostic value of TROP2 expression in patients with gallbladder cancer","author":"Chen","year":"2014","journal-title":"Tumour Biol"},{"key":"key-10.4103\/0377-4929.291691-24","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IGC.0b013e318228f6da","article-title":"Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: Implications for therapy with hRS7, a humanized anti-Trop-2 monoclonal antibody","author":"Bignotti","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"key-10.4103\/0377-4929.291691-25","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/cncr.25891","article-title":"Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody","author":"Varughese","year":"2011","journal-title":"Cancer"},{"key":"key-10.4103\/0377-4929.291691-26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ygyno.2011.03.002","article-title":"High grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody","author":"Varughese","year":"2011","journal-title":"Gynecol Oncol"},{"key":"key-10.4103\/0377-4929.291691-27","doi-asserted-by":"crossref","first-page":"567e1","DOI":"10.1016\/j.ajog.2011.06.093","article-title":"Cervical carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody","author":"Varughese","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"key-10.4103\/0377-4929.291691-28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12282-011-0316-z","article-title":"Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B","author":"Hayashi","year":"2013","journal-title":"Breast Cancer"},{"key":"key-10.4103\/0377-4929.291691-29","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2004.10.047","article-title":"Randomizedphase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracyclin, a taxane, or both","author":"Perez","year":"2004","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0377-4929.291691-30","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop2-SN-38 antibody conjugate (sacituzumab govitecan)","author":"Sharkey","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0377-4929.291691-31","unstructured":"Robboy SJ, Mutter GL, Prat J, Bentley RC, Russell P, Anderson MC. Endometrial adenocarcinoma. Robboy's Pathology of the Female Reproductive Tract. 2nd ed. Churchill Livingstone, Elsevier (UK\/USA); 2009. p. 393-426."},{"key":"key-10.4103\/0377-4929.291691-32","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1097-0142(19911115)68:10<2293::AID-CNCR2820681032>3.0.CO;2-V","article-title":"The significance of squamous differentiation in endometrial carcinoma data from a gynecologic oncology group study","author":"Zaino","year":"1991","journal-title":"Cancer"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:51:17Z","timestamp":1786733477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_783_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"alternative-id":["291691"],"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_783_19","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}